Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047149 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
A Phase 1 study, sponsored by University of Massachusetts, Worcester.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02047149 is a Phase 1 study that was terminated before completion, run by University of Massachusetts, Worcester. The registered enrollment target is 2 participants.
The verdict
NCT02047149, a Phase 1 study, was terminated before completion, sponsored by University of Massachusetts, Worcester.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Prospective nonrandomized phase I study The purpose of this study is to determine safety and efficacy of zileuton when added to dasatinib in patients with chronic myelogenous leukemia (CML).
Interventions
- DRUG Zileuton (Zyflo®) Dasatinib (Sprycel®)
- DRUG Dosing with Zileuton/Dasatinib in CML
- DRUG Daily dosing of Zileuton/Dasatinib
- DRUG Daily dosing with Zileuton/Dasatinib for CML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02047149
The ClinicalTrials.gov registry entry for NCT02047149 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Zileuton (Zyflo®) Dasatinib (Sprycel®) is the first listed.
NCT02047149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02047149 about?
NCT02047149 is a clinical study titled "Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia". Prospective nonrandomized phase I study The purpose of this study is to determine safety and efficacy of zileuton when added to dasatinib in patients with chronic myelogenous leukemia (CML).
What is the current status of trial NCT02047149?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2014-01. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02047149?
The interventions under investigation include: Zileuton (Zyflo®) Dasatinib (Sprycel®) (DRUG), Dosing with Zileuton/Dasatinib in CML (DRUG), Daily dosing of Zileuton/Dasatinib (DRUG), Daily dosing with Zileuton/Dasatinib for CML (DRUG).
Who is sponsoring clinical trial NCT02047149?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.